XPO, Inc.

XPO, Inc. is one of the largest providers of asset-based less-than-truckload (LTL) transportation in North America.

Following the spinoff of the contract logistics division (GXO) in 2021 as well as its freight brokerage operations (RXO) in 2022, XPO Logistics (NYSE: XPO) is moving closer to be the pure play asset-based less-than-truckload carrier.

As per our previous report on XPO as on October 26, 2022, a ‘Buy’ recommendation was given on the stock at $48.370, and noted below are the details of support and resistance provided in our previous report:

Recommendation Summary as on October 26, 2022 (prior to the spin-off)

Key Updates

XPO has announced that it has wrapped up the previously announced spin-off of RXO, Inc., which led to the creation of 2 independent as well as publicly traded companies. Now, RXO would begin “regular way” trading on NYSE under the symbol “RXO.”  

This separation was completed via a distribution to XPO stockholders of 1 share of RXO common stock for every 1 share of XPO common stock held as of the record date for the distribution (October 20, 2022). RXO shares were distributed at 12:01 a.m. (ET) on November 1, 2022. The distribution was intended to be tax-free to XPO stockholders. The opening stock price of RXO was $20.25 per share on November 1, 2022.

XPO’s Daily Chart

Source: REFINITIV; Analysis: Kalkine Group

Considering the current trading levels as well as risks associated, it is prudent to liquidate the stock at the current levels.

Hence, a ‘Sell’ rating has been provided on the stock at the closing price of $43.94 as of 2^nd February 2023. 

RXO, Inc.  

RXO, Inc. provides transportation solutions. It specializes in freight forwarding, truckload, and supply chain management, as well as offers data science, technology operations, and machine learning solutions.

As per our previous report on RXO as on 23 December 2022, a ‘Speculative Buy’ recommendation was given on the stock at $16.02, and noted below are the details of support and resistance provided in our previous report:

Recommendation Summary as on 23 December 2022 (post the spin-off)

Source: REFINITIV; Analysis: Kalkine Group 

Considering the current trading levels as well as risks associated, it is prudent to liquidate the stock at the current levels.

Since RXO Inc (NYSE: RXO) is trading separately, a ‘Sell’ rating has been provided on that stock as well at the closing price of $20.09 as of 2 February 2023. 

Note: This report may be updated with details around fundamental and technical analysis, price/ chart in due course, as appropriate.

Note 1: Past performance is neither an indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, currency and technical indicators is February 2, 2023. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Disclaimer

Kalkine New Zealand Limited is a Financial Advice Provider (“FAP”) and is authorised by a Transitional FAP license issued by Financial Markets Authority (“FMA”) to provide financial advice. Kalkine provides only general financial advice through its research reports following a person becoming a member. The reports contain buy/sell/hold and other recommendations in relation to equity financial products. The recommendations and opinions [on this website] / [in this report] do not take into account any of your investment objectives, financial situation or needs. Before you make a decision about whether to acquire a financial product, you should obtain the Product Disclosure Statement from the product issuer. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. If you act on the advice in the research reports, you may have to pay fees, expenses or other amounts (but not to Kalkine).  Further information about the complaints and dispute resolution process, as well as information about Kalkine’s duties are available on Kalkine’s website.  Please read our Financial Advice Provider (FAP) disclosure statement and Complaints Handling Guide, which are available on the website.